Research has shown PRL3 mediates its oncogenic function in AML by activating canonical Wnt signaling 60, 138, Consequently, AML cells overexpressing PRL3 have enhanced sensitivity towards β-catenin inhibition both in vitro and in vivo138. The gene discussed is PTP4A3; the disease is acute myeloid leukemia.